PURPOSE: In the first years of imatinib treatment, BCR-ABL remained detectable in all but a small minority of patients with chronic myeloid leukemia. We determined whether BCR-ABL continues to decline with longer imatinib exposure and the incidence and consequence of undetectable BCR-ABL. EXPERIMENTAL DESIGN:BCR-ABL levels were measured in a subset of 53 imatinib-treated IRIS trial patients for up to 7 years (29 first-line, 24 second-line). Levels were deemed undetectable using strict PCR sensitivity criteria. RESULTS: By 18 months, the majority achieved a 3-log reduction [major molecular response (MMR)]. BCR-ABL continued to decline but at a slower rate (median time to 4-log reduction and undetectable BCR-ABL of 45 and 66 months for first-line). The probability of undetectable BCR-ABL increased considerably from 36 to 81 months of first-line imatinib {7% [95% confidence interval (95% CI), 0-17%] versus 52% (95% CI, 32-72%)}. Undetectable BCR-ABL was achieved in 18 of 53 patients and none of these 18 lost MMR after a median follow-up of 33 months. Conversely, MMR was lost in 6 of 22 (27%) patients with sustained detectable BCR-ABL and was associated with BCR-ABL mutations in 3 of 6. Loss of MMR was recently defined as suboptimal imatinib response. There was no difference in the probability of achieving molecular responses between first- and second-line patients but first-line had a significantly higher probability of maintaining MMR [P = 0.03; 96% (95% CI, 88-100%) versus 71% (95% CI, 48-93%)]. CONCLUSIONS: With prolonged therapy, BCR-ABL continued to decline in most patients and undetectable BCR-ABL was no longer a rare event. Loss of MMR was only observed in patients with sustained detectable BCR-ABL.
RCT Entities:
PURPOSE: In the first years of imatinib treatment, BCR-ABL remained detectable in all but a small minority of patients with chronic myeloid leukemia. We determined whether BCR-ABL continues to decline with longer imatinib exposure and the incidence and consequence of undetectable BCR-ABL. EXPERIMENTAL DESIGN:BCR-ABL levels were measured in a subset of 53 imatinib-treated IRIS trial patients for up to 7 years (29 first-line, 24 second-line). Levels were deemed undetectable using strict PCR sensitivity criteria. RESULTS: By 18 months, the majority achieved a 3-log reduction [major molecular response (MMR)]. BCR-ABL continued to decline but at a slower rate (median time to 4-log reduction and undetectable BCR-ABL of 45 and 66 months for first-line). The probability of undetectable BCR-ABL increased considerably from 36 to 81 months of first-line imatinib {7% [95% confidence interval (95% CI), 0-17%] versus 52% (95% CI, 32-72%)}. Undetectable BCR-ABL was achieved in 18 of 53 patients and none of these 18 lost MMR after a median follow-up of 33 months. Conversely, MMR was lost in 6 of 22 (27%) patients with sustained detectable BCR-ABL and was associated with BCR-ABL mutations in 3 of 6. Loss of MMR was recently defined as suboptimal imatinib response. There was no difference in the probability of achieving molecular responses between first- and second-line patients but first-line had a significantly higher probability of maintaining MMR [P = 0.03; 96% (95% CI, 88-100%) versus 71% (95% CI, 48-93%)]. CONCLUSIONS: With prolonged therapy, BCR-ABL continued to decline in most patients and undetectable BCR-ABL was no longer a rare event. Loss of MMR was only observed in patients with sustained detectable BCR-ABL.
Authors: Wendy Deenik; Jeroen J W M Janssen; Bronno van der Holt; Gregor E G Verhoef; Willem M Smit; Marie José Kersten; Simon M G J Daenen; Leo F Verdonck; Augustin Ferrant; Anton V M B Schattenberg; Pieter Sonneveld; Marinus van Marwijk Kooy; Shulamit Wittebol; Roelof Willemze; Pierre W Wijermans; H Berna Beverloo; Bob Löwenberg; Peter J M Valk; Gert J Ossenkoppele; Jan J Cornelissen Journal: Haematologica Date: 2009-12-16 Impact factor: 9.941
Authors: Hagop Kantarjian; Susan O'Brien; Jorge Cortes; William Wierda; Stefan Faderl; Guillermo Garcia-Manero; Jean-Pierre Issa; Elihu Estey; Michael Keating; Emil J Freireich Journal: Cancer Date: 2008-10-01 Impact factor: 6.860
Authors: Timothy P Hughes; Andreas Hochhaus; Susan Branford; Martin C Müller; Jaspal S Kaeda; Letizia Foroni; Brian J Druker; François Guilhot; Richard A Larson; Stephen G O'Brien; Marc S Rudoltz; Manisha Mone; Elisabeth Wehrle; Vijay Modur; John M Goldman; Jerald P Radich Journal: Blood Date: 2010-08-02 Impact factor: 22.113